Motivated by a stock price that tripled over the past 10 days and in real need for new cash, MannKind (MNKD) sold 10 million shares in an overnight stock offering priced at $6 per share. After fees, the sale nets the struggling peddler of Afrezza, an inhaled insulin, just under $58 million.

MannKind remains a failing business with a bloated $700 million market valuation, so think of the new financing as a small bandage on a gaping wound. The company burned through $23 million in cash during the third quarter while managing to sell (on a net basis) just $1.8 million to $2.2 million of Afrezza, according to preliminary financial results disclosed Wednesday.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy